Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sanofi to buy hepatitis vaccine maker Dynavax in $2.2bn deal

(Sharecast News) - France's Sanofi said on Wednesday that it has agreed to buy US hepatitis vaccine maker Dynavax in a $2.2bn deal. Dynavax's adult hepatitis B vaccine is currently marketed in the US, while its shingles vaccine candidate is in phase 1/2 clinical development.

The company said the acquisition augments its presence in adult immunisation by bringing together Dynavax's vaccines with Sanofi's "global scale, development capabilities and commercial reach".

Under the terms of the deal, Sanofi will start a cash tender offer to buy all outstanding shares of Dynavax for $15.50 per share.

Thomas Triomphe, executive vice president of vaccines at Sanofi, said: "Dynavax enhances Sanofi's adult immunisation presence by adding differentiated vaccines that complement Sanofi's expertise.

"Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan."

The acquisition, which is due to close in the first quarter of next year, is not expected to have any impact on Sanofi's financial guidance for 2025.

Share this article

Related Sharecast Articles

Deutsche Bank downgrades B&M, Wickes, Currys and Dunelm
(Sharecast News) - Deutsche Bank downgraded a host of UK retailers on Friday, saying the biggest debate right now is whether we are in the "calm before the storm" with regards the inflationary impact on consumer spending and retailer margins or whether we are creating a "storm in a teacup".
Deutsche Bank downgrades B&M, Wickes, Currys and Dunelm
(Sharecast News) - Deutsche Bank downgraded a host of UK retailers on Friday, saying the biggest debate right now is whether we are in the "calm before the storm" with regards the inflationary impact on consumer spending and retailer margins or whether we are creating a "storm in a teacup".
BoE's Bailey says above‑target inflation tolerable for now amid Middle East uncertainty
(Sharecast News) - Bank of England governor Andrew Bailey said on Friday that allowing inflation to sit above the central bank's 2% target was justified for now, given the uncertainty created by the Iran war and the UK's weak growth backdrop.
Dell surges as AI boom drives record revenue growth
(Sharecast News) - Dell Technologies posted its strongest revenue growth since returning to public markets on Thursday, comfortably beating Wall Street expectations and sending shares as much as 39% higher in extended trading.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.